DOCSLIB.ORG

Paraneoplastic Syndromes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paraneoplastic Syndromes NEUROLOGICAL REVIEW Paraneoplastic Syndromes Josep O. Dalmau, MD, PhD; Jerome B. Posner, MD he fact that a small cancer hidden in the chest, abdomen, or pelvis could destroy or damage portions of the nervous system, such as cerebellar Purkinje cells or choliner- gic synapses, has intrigued neurologists since paraneoplastic syndromes were first de- scribed. In 1965, when little was known about their pathogenesis, a full issue of the Tjournal Brain and an international symposium were devoted to paraneoplastic disorders. In this decade, the discovery of several paraneoplastic antibodies that react with both the nervous system and the causal cancer has rekindled interest in these syndromes (Table). Several other factors make these rare syndromes of clinical and scientific interest. A recent review by Dalmau and Posner1 contains a more comprehensive bibliography of paraneoplastic syndromes. These disorders challenge the diagnostic both patients, cancer of the breast was skills of the neurologist. The patient’s can- subsequently discovered. The anti-Ta an- cer has usually not yet been discovered tibody seems to be specific for testicular and, because other inflammatory disor- cancer. ders of the nervous system can mimic para- Paraneoplastic syndromes are a thera- neoplastic syndromes, the diagnosis is of- peutic challenge for the neurologist. With ten difficult. However, paraneoplastic the exception of myasthenia gravis, the antibodies, in most (but not all) in- Lambert-Eaton myasthenic syndrome, neu- stances, unequivocally establish that the romyotonia, dermatomyositis, and cer- disorder is paraneoplastic. tain peripheral neuropathies associated with The disorders challenge the diagnos- myeloma, treatment of paraneoplastic syn- tic skills of the oncologist. The underly- dromes is generally unsatisfactory. ing cancer may be so small as to be unde- Paraneoplastic syndromes are a thera- tectable by even the most sophisticated peutic challenge for the oncologist. Sub- imaging techniques. Fortunately, many stantial evidence suggests that in patients paraneoplastic antibodies also point to the with paraneoplastic antibody-positive se- most likely underlying tumor. For ex- rology, the neoplasms grow more indo- ample, the anti-Hu antibody indicates the lently and are less likely to metastasize than presence of a small cell lung cancer and in patients with the same cancer who are the anti-Yo antibody, the presence of an not antibody positive or who do not have ovarian or breast cancer. So strong is the paraneoplastic symptoms.2 Recent animal association of the anti-Yo antibody with data support these conclusions.3 If the neu- gynecologic cancers that we and others rec- rologist chooses to treat the neurologic ommend hysterectomy and salpingo- symptoms with immune suppression, it is oophorectomy in anti-Yo–positive post- possible that the oncologist will be faced menopausal patients with normal with a more rapidly growing tumor. mammograms, even in the absence of posi- Paraneoplastic antibodies react with tive imaging studies of the pelvis. In only both the cancer and the nervous system. 2 patients of whom we are aware has a can- These antibodies identify antigens, pres- cer not been found at pelvic surgery. In ent normally only in the nervous system (usually in neurons), but for uncertain rea- From the Department of Neurology, Memorial Sloan-Kettering Cancer Center, New sons expressed ectopically in certain tu- York, NY. mors. The immune system recognizes the ARCH NEUROL / VOL 56, APR 1999 405 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 Antineuronal Antibody–Associated Paraneoplastic Disorders* Onconeuronal Antibody Associated Cancer Syndrome Antigen Antigen Anti-Hu SCLC and neuroblastoma Encephalomyelitis, sensory neuronopathy All neuronal nuclei, 35-40 kd HuD, HuC, and Hel-N1 Anti-Yo Gynecologic and breast Cerebellar degeneration Cytoplasm Purkinje cells, CDR34, CDR62-1, 34 and 62 kd and CDR62-2 Anti-Ri Breast, gynecologic, Cerebellar ataxia, opsoclonus Neuronal nuclei CNS, NOVA1 and NOVA2 and SCLC 55 and 80 kd Antiamphiphysin Breast Stiff-man, encephalomyelitis Synaptic vesicles, 128 kd Amphiphysin Anti-VGCC SCLC Lambert-Eaton myasthenic syndrome Presynaptic VGCC a1-Subunit Anti-MysB SCLC Lambert-Eaton myasthenic syndrome Presynaptic VGCC b-Subunit VGCC Anti-Ma Multiple Cerebellar, brainstem dysfunction Neuronal nuclei and cytoplasm, Ma1 and Ma2 37 and 40 kd Anti-Ta Testicular Limbic encephalitis, brainstem dysfunction Neuronal nuclei and cytoplasm, 40 kd Ma2 Anti-Tr Hodgkin lymphoma Cerebellar degeneration Cytoplasm neurons, Purkinje cells, In progress and spiny dendrites Anti-CAR SCLC and others Photoreceptor degeneration Retinal photoreceptor, 23 kd Recoverin Anti-CV2 SCLC and others Encephalomyelitis, cerebellar degeneration Glia (subset), 66 kd POP66 *Data modified from Dalmau and Posner.1 SCLC indicates small cell lung cancer; CNS, central nervous system; VGCC, voltage-gated calcium channels; and CAR, carcinoma-associated retinopathy. proteins expressed by the tumor as foreign and mounts acute sensory neuronopathy associated with lung can- an immune attack that partially controls tumor growth cer had in their serum a low-titer antibody that reacted (in some instances it appears to destroy the tumor so that with the cytoplasm [sic] of neurons in the guinea pig ce- no tumor is found even at autopsy). The immune reac- rebral cortex. No additional information was forthcom- tion also attacks portions of the nervous system that ex- ing until 1985, when Graus and colleagues7 described first press the antigen. The pathogenesis of some syndromes 2 and later 4 patients with subacute sensory neuropathy (myasthenia gravis, Lambert-Eaton myasthenic syn- associated with small cell lung cancer who had in their drome, neuromyotonia) is mediated by antibodies but, serum high titers of a complement-fixing antibody that for the majority of antibody-associated paraneoplastic syn- reacted predominantly with the nuclei of central and pe- dromes of the central nervous system (CNS), the major ripheral nervous system neurons. The Hu antigens cor- pathogenic mechanism appears to be related to cyto- respond to a set of proteins of 35 to 40 kd on Western toxic T-cell responses.4 blot using either neuronal or small cell lung cancer pro- In paraneoplastic syndromes affecting the CNS, in- tein extracts. Subsequently, it has become evident that flammatory infiltrates of T cells and plasma cells are found the anti-Hu antibody is a marker not only of sensory both in the nervous system and in the cancer. Further- neuronopathy but also of encephalomyelitis. more, IgG normally absent from the CNS can be found Subsequent work has identified several proteins be- not only within the neuropil but also within neurons. Elu- longing to the Hu family. All of these have high homol- tion studies indicate that the antibody found in the brain ogy with the Drosophila embryonic lethal abnormal vi- and the tumors of patients with paraneoplastic syn- sual (ELAV) protein, necessary for the development of dromes is the same antibody that reacts with onconeu- the eye and the CNS of the fly. All Hu proteins, includ- ral antigens.5 ing HuD, HuC, Hel-N1, and HuR, contain 2 tandem RNA Because onconeural antigens are normally present recognition motifs (RRM), a basic domain, and a third only in neurons, it is likely that they are important for neu- RRM. The basic domains of HuD, Hel-N1, and HuC are ral development and phenotype maintenance. Accord- alternatively spliced yielding HuDpro, HuDmex, Hel- ingly, we and others have used paraneoplastic antibodies N2, and HuC isoforms. The expression of HuD, HuC, and to probe complementary DNA expression libraries to clone Hel-N1 is restricted to neurons, but HuR is reported to the antigen(s) identified by these antibodies (Table). With be ubiquitously expressed in extraneuronal tissues.8 These respect to those antigens that have been identified so far, proteins bind to AU-rich elements, which are present in the molecular analysis appears to confirm that onconeu- the 39-untranslated region of messenger RNA (mRNA), ral antigens are important to neuronal function. The re- that regulate cell proliferation (ie, c-fos, c-Myc, Gap43, mainder of this article will address the question of the func- and GM-CSF). The exact function of the Hu proteins re- tion of some onconeural antigens. mains unknown, but it has been postulated that they act as transfactors involved in selective mRNA degradation. Hu ANTIGENS The anti-Hu antibodies bind to the first and second RRM of HuD, HuC, and Hel-N1 but not HuR; it is un- The term Hu antigens refers to a family of nuclear pro- known how the binding of anti-Hu antibodies may af- teins normally expressed in all neurons of the central and fect the function of these proteins, but for HuD the first peripheral nervous system but not in other cell types (with and second RRM are essential for RNA binding. the possible exception of the testes). The antigen was prob- Although a study of the developing mouse nervous ably first identified by Wilkinson and Zeromski6 in 1965, system has demonstrated a hierarchy of expression of the when they reported that 4 patients suffering from sub- Hu proteins, in the adult mouse, all Hu proteins appear ARCH NEUROL / VOL 56, APR 1999 406 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 to be expressed in most brain regions.9 The same study cho et al,13 is a 34-kd protein that consists of 34 inexact showed that dorsal root ganglia, which in about 70% of tandem repeats of a hexapeptide. Amino acids 2, 3, 4, and patients with the anti-Hu syndrome is the initial target 6 in this hexapeptide are invariably leucine, glutamate, of the disease, has a robust expression of the 4 mouse aspartate, and aspartate, respectively. Amino acids 1 and Hu homologs. The Hu proteins are an early marker of 5 are more variable—1 being leucine or phenylalanine neuronal development.10 Although not present in neu- and 5 being methionine or valine.
Load more

Recommended publications
  • Electrolyte Disorders in Cancer Patients: a Systematic Review
    Berardi et al. J Cancer Metastasis Treat 2019;5:79 Journal of Cancer DOI: 10.20517/2394-4722.2019.008 Metastasis and Treatment Review Open Access Electrolyte disorders in cancer patients: a systematic review Rossana Berardi, Mariangela Torniai, Edoardo Lenci, Federica Pecci, Francesca Morgese, Silvia Rinaldi Clinica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Ancona 60126, Italy. Correspondence to: Prof. Rossana Berardi, Clinica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero- Universitaria Ospedali Riuniti di Ancona, Via Conca 71, Ancona 60126, Italy. E-mail: [email protected] How to cite this article: Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S. Electrolyte disorders in cancer patients: a systematic review. J Cancer Metastasis Treat 2019;5:79. http://dx.doi.org/10.20517/2394-4722.2019.008 Received: 26 Apr 2019 First Decision: 26 Jul 2019 Revised: 20 Nov 2019 Accepted: 20 Nov 2019 Published: 9 Dec 2019 Science Editor: Stephen J. Ralph Copy Editor: Jing-Wen Zhang Production Editor: Jing Yu Abstract Electrolyte disorders are very common complications in cancer patients. They might be associated to a worsening outcome, influencing quality of life, possibility to receive anticancer drugs, and conditioning survival. In fact, they might provoke important morbidity, with dysfunction of multiple organs and rarely causing life-threatening conditions. Moreover, recent studies showed that they might worsen cancer patients’ outcome, while a prompt correction seems to have a positive impact. Furthermore, there is evidence of a correlation between electrolyte alterations and poorer performance status, delays in therapy commencement and continuation, and negative treatment outcomes.
    [Show full text]
  • Paraneoplastic Encephalomyelitis: Is It an Oropharyngeal Or a Lung Cancer Complication?
    ONCOLOGY LETTERS 2: 171-174, 2011 Paraneoplastic encephalomyelitis: Is it an oropharyngeal or a lung cancer complication? MARÍA SERENO Moyano1, GERARDO GUTIÉRREZ-GUTIÉRREZ2, CÉSAR GÓMEZ-RAPOSO1, MIRIAM LÓPEZ GÓMEZ1, JOAQUÍN OJEDA2, AmBroSio mirAlleS2 and ENRIQUE CASADO-SÁENZ1 Departments of 1Oncology, and 2Neurology, Infanta Sofía Hospital, San Sebastián de los Reyes, Madrid, Spain Received September 30, 2010; Accepted November 12, 2010 DOI: 10.3892/ol.2010.224 Abstract. This case report describes a patient with a locally tumor and the nervous system suggests that these disorders advanced oropharyngeal cancer with a simultaneous para- are immune-mediated. Numerous onconeural antibodies have neoplastic encephalomyelitis. To the best of our knowledge, a been described, but less than 50% of patients with PNS harbor paraneoplastic neurological syndrome is a rare complication these types of proteins. in head and neck cancer, and has previously not been reported Therefore, the absence of paraneoplastic antibodies in the literature. One year later, following initial treatment, does not exclude the diagnosis of PNS. The main neuro- a small cell lung cancer developed, a tumor frequently logical syndromes associated with paraneoplastic origin associated with this type of paraneoplastic syndrome. The include limbic encephalitis, subacute cerebellar ataxia, dilemma, therefore, is whether this paraneoplastic symdrome opsoclonus-myoclonus, retinopathies, chronic gastrointestinal was a secondary complication of the tonsilar concurrent cancer pseudoobstruction, sensory neuronopathy, Lambert-Eaton or a metachronous paraneoplastic syndrome prior to small myasthenic syndrome and encephalomyelitis (3). cell lung cancer. The majority of tumors associated with PNS are small cell lung cancer (SCLC), ovarian cancer and hematological Introduction diseases, mainly lymphomas. PNS in HNC is extremely rare.
    [Show full text]
  • PARANEOPLASTIC SYNDROMES: J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.2004.040378 on 14 May 2004
    PARANEOPLASTIC SYNDROMES: J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.040378 on 14 May 2004. Downloaded from WHEN TO SUSPECT, HOW TO CONFIRM, AND HOW TO MANAGE ii43 J H Rees J Neurol Neurosurg Psychiatry 2004;75(Suppl II):ii43–ii50. doi: 10.1136/jnnp.2004.040378 eurological manifestations of cancer are common, disabling, and often multifactorial (table 1). The concept that malignant disease can cause damage to the nervous system Nabove and beyond that caused by direct or metastatic infiltration is familiar to all clinicians looking after cancer patients. These ‘‘remote effects’’ or paraneoplastic manifestations of cancer include metabolic and endocrine syndromes such as hypercalcaemia, and the syndrome of inappropriate ADH (antidiuretic hormone) secretion. Paraneoplastic neurological disorders (PNDs) are remote effects of systemic malignancies that affect the nervous system. The term PND is reserved for those disorders that are caused by an autoimmune response directed against antigens common to the tumour and nerve cells. PNDs are much less common than direct, metastatic, and treatment related complications of cancer, but are nevertheless important because they cause severe neurological morbidity and mortality and frequently present to the neurologist in a patient without a known malignancy. Because of the relative rarity of PND, neurological dysfunction should only be regarded as paraneoplastic if a particular neoplasm associates with a remote but specific effect on the nervous system more frequently than would be expected by chance. For example, subacute cerebellar ataxia in the setting of ovarian cancer is sufficiently characteristic to be called paraneoplastic cerebellar degeneration, as long as other causes have been ruled out.
    [Show full text]
  • Paraneoplastic Syndromes in Lung Cancer and Their Management
    359 Review Article Page 1 of 9 Paraneoplastic syndromes in lung cancer and their management Asad Anwar1, Firas Jafri1, Sara Ashraf2, Mohammad Ali S. Jafri3, Michael Fanucchi3 1Department of Internal Medicine, Westchester Medical Center, Valhalla, NY, USA; 2Department of Hematology/Oncology, Marshall University, Huntington, WV, USA; 3Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Mohammad Ali S. Jafri, MD. Department of Hematology/Oncology, Westchester Medical Center, Valhalla, NY, USA. Email: [email protected]. Abstract: Paraneoplastic syndromes are most frequently associated with lung cancer. This review considers a variety paraneoplastic syndromes associated with lung cancer and discusses their pathophysiology, clinical features and management options. Keywords: Paraneoplastic syndromes; lung cancer; thoracic oncology Submitted Feb 12, 2019. Accepted for publication Apr 25, 2019. doi: 10.21037/atm.2019.04.86 View this article at: http://dx.doi.org/10.21037/atm.2019.04.86 Introduction PTHrP production (parathyroid hormone related-protein), it is referred to as HHM. Paraneoplastic syndromes refer to the remote effects HHM is observed in a variety of malignancies such as associated with malignancy which are unrelated to direct breast, renal, multiple myeloma and lung; squamous cell tumor invasion or metastases (1). These may occur before is the most frequently observed subtype (3-5). Osteolytic the cancer is diagnosed and can be independent in their metastases are another significant cause of hypercalcemia in severity to the stage of the primary tumor.
    [Show full text]
  • Lung Cancer and Paraneoplastic Syndromes
    Lung Cancer and Paraneoplastic Syndromes AmitaVasoya D.O., FACOI, FCCP, FAASM Christiana Care Pulmonary Associates Clinical Assistant Professor of Medicine Sidney Kimmel Medical College of Thomas Jefferson University Rowan University School of Osteopathic Medicine ACOI Board Review 2018 Disclosures None Introduction Lung cancer is the most common cause of mortality WORLDWIDE 1.3 million deaths per year In U.S. 2012: 226,000 new cases American Cancer Society Facts & Figures 2012 Incidence CDC, National Cancer Institute 2013 Incidence CDC, National Cancer Institute 2013 5 year Survival Rates National Cancer Institute 2008 Death Rate CDC, National Cancer Institute 2013 Death Rate CDC, National Cancer Institute 2013 Risk Factors SMOKING Environmental ◦ Radon ◦ Air pollution ◦ Metals Asbestos Genetics HIV Pulmonary Fibrosis Radiation therapy Lung Cancer Encompasses all tumors which arise from the bronchi, bronchioles, alveoli, and other respiratory epithelium Mesotheliomas, lymphomas, and sarcomas are distinct from the epithelial derived cancers Lung Cancer Primary ◦ Bronchogenic ◦ Carcinoid ◦ Adenoid Cystic Carcinoma ◦ Mucoepidermoid Soft Tissue ◦ Sarcoma Metastatic Primary Lung Cancer: Bronchogenic Carcinoma Small Cell Non Small Cell ◦ Classic small Cell ◦ Squamous ◦ Large Cell ◦ Adenocarcinoma Neuroendocrine “Bronchoalveolar cell” ◦ Combined Atypical adenomatous hyperplasia (AAH) Adenocarcinoma in-situ (AIS) Minimally invasive adenocarcinoma ◦ Large Cell Lung Cancer According to the WHO classification 88% of all primary
    [Show full text]
  • Rheumatologic Diseases As Paraneoplastic Syndromes
    ISSN: 2469-5726 de Figueiredo et al. J Rheum Dis Treat 2018, 4:067 DOI: 10.23937/2469-5726/1510067 Volume 4 | Issue 4 Journal of Open Access Rheumatic Diseases and Treatment CASE REPORT Rheumatologic Diseases as Paraneoplastic Syndromes - A Para- digmatic Case Inês Rego de Figueiredo*, Rita Vieira Alves, Sara Guerreiro Castro, Filipa Lourenço, Ana Margarida Antunes, Heidi Gruner and António Panarra Check for Serviço de Medicina 7.2 - Hospital Curry Cabral, Centro Hospitalar e Universitário de Lisboa Central (CHULC), updates Portugal *Corresponding author: Inês Rego de Figueiredo, Serviço de Medicina 7.2 - Hospital Curry Cabral, Centro Hospitalar e Universitário de Lisboa Central (CHULC), Rua da Beneficiência 8, 1050-099 Lisboa, Portugal hypothesized: 1) Both neoplasia and rheumatic disease Abstract have the same trigger [2], 2) Toxins produced by the Rheumatic diseases can be a paraneoplastic syndrome for an occult neoplasia. Some syndromes are more characteris- tumor trigger inflammation and therefore the rheumat- tic than others. In this case report, we present a patient with ic disease [2], 3) Paraneoplastic rheumatic syndromes musculoskeletal symptoms suggestive of both carcinomatous consist on hypersensitivity reactions, against the intra- arthritis and polymyalgia rheumatica that was shown to have cellular antigens eliminated by apoptotic cancer cells adenocarcinoma of the lung. The musculoskeletal symptoms [6], 4) Rheumatic paraneoplastic diseases represent a accompanied the course of the disease, disappearing with the treatment and re-occurring when it relapsed. successful tumor immunosurveillance [7]. Some features of the rheumatic disease should Introduction raise suspicion of paraneoplastic syndromes and start a prompt study [3]. Those are: personal or familiar cancer A variety of rheumatic syndrome are associated with history, exposition to carcinogens, or immunosuppres- neoplasia [1].
    [Show full text]
  • Management of Immune-Mediated Paraneoplastic Neurological Disorders
    Review Management of Immune-Mediated Paraneoplastic Neurological Disorders Authors Ilya Ayzenberg, Ralf Gold, Ingo Kleiter Affiliation ABStraCT Department of Neurology, St. Josef Hospital, Ruhr University Paraneoplastic neurological disorders are rare and clinically Bochum, Germany heterogeneous diseases. They can affect both the central and peripheral nervous system as well as the neuromuscular junc- Key words tion and muscle. Neurological deficits develop in 2/3 of cases paraneoplastic, autoantibody, encephalitis, polyneuropathy prior to cancer diagnosis. The diagnostic approach includes screening for antineuronal antibodies and a search for the un- Bibliography derlying tumor. A prompt tumor therapy in combination with DOI https://doi.org/10.1055/s-0043-112730 immunotherapy is the cornerstone in the management of Neurology International Open 2017; 1: E264–E274 these diseases. Due to lack of clinical trials, treatment recom- © Georg Thieme Verlag KG Stuttgart · New York mendations are based on case series and expert opinions. High- ISSN 2511-1795 dose corticosteroids, intravenous immunoglobulins and apher- esis therapies are often used in the acute stage of the disease. Correspondence These therapies should be started as early as possible, e. g., Dr. Ilya Ayzenberg during tumor screening, in order to prevent irreversible dam- Klinik für Neurologie St. Josef Hospital Ruhr-Universität age. Long-term treatment is mostly immunosuppressive and Bochum depends on the specific paraneoplastic syndrome. Outcomes Gudrunstr. 56 vary depending upon the prognosis of the underlying cancer 44791 Bochum and the nature of the antineuronal antibodies. Disorders with Germany antibodies directed against antigens on the neuronal cell sur- [email protected] face are highly sensitive to B cell-directed therapies and most- ly associated with a favorable outcome.
    [Show full text]
  • Paraneoplastic Syndromes in Rheumatology
    PRACA POGLĄDOWA Varia Medica 2018 tom 2, nr 4, strony 359–363 Copyright © 2018 Via Medica ISSN 2544-4212 Paraneoplastic syndromes in rheumatology Zespoły paranowotworowe w reumatologii Beata Dubiel-Braszczok1, Magdalena Włoch-Targońska2, Przemysław Kotyla2 1Oncology Ward, Prof. Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia in Katowice 2Chair and Clinic of Internal Medicine and Rheumatology, Faculty of Medicine in Katowice, Medical University of Silesia in Katowice Streszczenie Zespoły paranowotworowe są to objawy lub zespoły objawów towarzyszące chorobie nowotworowej, które często ustępu- ją po skutecznym wyleczeniu nowotworu. Przyczyny zespołów paranowotworowych nie zostały w pełni poznane. Mechani- zmy związane są z nieprawidłowym wydzielania hormonów lub cytokin, a także z wytwarzaniem przeciwciał skierowanych przeciw nowotworowi. Najczęstsze zespoły paranowotworowe objawiają się pod postacią zespołów neurologicznych, zaburzeń hematologicznych, zmian skórnych. Artykuł przedstawia związek nowotworów złośliwych z autoimmunologicz- nymi chorobami tkanki łącznej. Słowa kluczowe: zespoły paranowotworowe, nowotwory złośliwe, choroby tkanki łącznej Przedrukowano za zgodą z: Forum Reumatologiczne 2018; 4 (2): 108–112 Abbreviations This article presents typical rheumatic entities which may be related to or directly caused by the expansive pro- RA — Rheumatoid arthritis cess ongoing within the body. SLE — Systemic lupus erythematosus The relation between cancer and autoimmune rheu- PM — Polymyositis matic diseases is sufficiently understood; it is assumed DM — Dermatomyositis that progression of the process may occur due to activa- NHL — Non-Hodgkin lymphomas tion of multiple potential mechanisms. Cancer may occur HL — Hodgkin’s lymphoma as a consequence of rheumatic diseases due to chronic inflammation in the tumour microenvironment [1, 2], dama- Introduction ge caused by the rheumatic process or cytostatic therapy.
    [Show full text]
  • A Study of Paraneoplastic Syndrome Patterns in Patients with Bronchogenic Carcinoma
    Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 A Study of Paraneoplastic Syndrome Patterns in Patients with Bronchogenic Carcinoma Vurgese Thomas Abraham, MD, MRCP (UK)* Bahl Sunil Radhakrishna, MBBS, MD** Mapkar Osman Abdulwahab, MBBS, MD* Background: Paraneoplastic syndromes, which are the distant effect of underlying carcinoma, which can present early, well before the primary lung lesion produces local symptoms and even when the tumor is undetected or very small. Paraneoplastic syndromes are common in patients with bronchogenic carcinoma. They may be the presenting finding or the first sign of recurrence. Aims: To assess the incidence and pattern of paraneoplastic syndrome (PNS) in patients with bronchogenic carcinoma. Settings: Peripheral Hospital in Kuwait. Design: Retrospective study. Methods: A retrospective study of 52 confirmed bronchogenic carcinoma patients occurring from January 2000 to June 2004 in our hospital was carried out. The Medical records of all the confirmed cases of bronchogenic carcinoma admitted between January 2000 and June 2004 were reviewed. The clinical and biochemical parameters recorded were: age, sex, underlying medical illness, presentation complete blood count, blood urea, electrolytes and serum calcium levels, and appropriate hormone levels where indicated. The localization of the tumors was done by chest x-ray and CT scan. Tissue biopsy was obtained by bronchoscopy or under CT scan guidance and histopathological examination of the specimen was carried out. The type and pattern of PNS if any was noted. These parameters were entered into a database and later analyzed. Statistical analysis used: The data management and statistical package used was Epi Info version 6 provided readily by the CDC (Centre for Disease Control) Bethesda USA.
    [Show full text]
  • A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma
    Case Report A Rare Coexistence of Paraneoplastic Cerebellar Degeneration: Papillary Thyroid Carcinoma Zeynep Özözen Ayas * and Gülgün Uncu Eskisehir City Hospital, Department of Neurology, Eskisehir 26080, Turkey; [email protected] * Correspondence: [email protected] Received: 18 November 2020; Accepted: 30 December 2020; Published: 19 January 2021 Abstract: Paraneoplastic cerebellar degeneration (PCD) is a rare neuroimmunological disease that may accompany tumors. In this article, we present a patient with progressive gait difficulty who was diagnosed with PCD and, in a rare comorbidity, with papillary thyroid carcinoma (PTC) following malignancy screening. A 46-year-old male patient reported having experienced poor balance for 2 years. A neurological examination revealed nystagmus, intention tremor, and ataxia, and anti-thyroid peroxidase and anti-thyroglobulin levels were found to be elevated. A brain MRI showed significant cerebellar atrophy in the superior vermis. Malignancy screening for PCD was performed, and thyroid ultrasonography revealed a nodule in the left lobe, while PET/CT detected elevated focal F-18 fluorodeoxyglucose uptake in the thyroid. Onconeuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-amphiphysin, anti-Tr, anti-PPCA-2, anti-Ma, anti-CV-1, and anti-ANNA-3) were negative. Pathologic examination of the thyroid revealed PTC, for which the patient was treated with 0.4 g/kg intravenous immunoglobulin and referred to the medical oncology department. This case demonstrates that clinicians must be alert to the rare comorbidity of PCD and PTC. Keywords: paraneoplastic cerebellar degeneration; ataxia; papillary thyroid carcinoma 1. Introduction Paraneoplastic neurological syndromes (PNSs) are diseases associated with malignancy that involve the nervous system (central, peripheral, and autonomic), which is affected by the immune system through different immunological pathways.
    [Show full text]
  • Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma
    Iran J Pediatr. 2015 February; 25(1):e266. DOI: 10.5812/ijp.266 Research Article Published online 2015 February 21. Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma 1 2 3 1 1,* Yu-tong Zhang ; Li-hua Feng ; Zhen Zhang ; Xiao-dan Zhong ; Jian Chang 1Department of Pediatric Hematology and Oncology, First Hospital of Jilin University, Changchun, China 2Department of Obstetrics and Gynecology, First Hospital of Jilin University, Changchun, China 3Department of Pediatric Intensive Care Unit, First Hospital of Jilin University, Changchun, China *Corresponding author : Jian Chang, 71 Xinmin Street, Department of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun 130021, Jilin, China. Tel: +86-43188782979, E-mail: [email protected] Received: ; Revised: ; Accepted: May 18, 2014 December 12, 2014 December 30, 2014 Background: Clinical presentations of paraneoplastic syndromes in neuroblastoma may multiply. Review of the clinical data and the literature on this syndrome may help in the diagnosis of neuroblastoma. Objectives: In order to make more accurate diagnosis, we reviewed the clinical data and the literature on this syndrome. Patients and Methods: Between April 2007 and April 2012, 68 children were diagnosed with neuroblastoma or ganglioneuroblastoma in our institution, 9 of which presented exclusively with paraneoplastic syndromes and were not treated with chemotherapy prior to diagnosis. After the diagnosis, all patients received chemotherapy and operation on NB97 protocol. Results: Among 68 pediatric patients with neuroblastoma or ganglioneuroblastoma, 4 (5.9%) patients suffered from neurological complications at diagnosis, 2 (2.9%) patients had digestive tract disorders, 2 (2.9%) patients had immune diseases, and 1 (1.5%) suffered from hematological disorder (without bone marrow involvement).
    [Show full text]
  • Paraneoplastic Syndromes in Patients with Primary Malignancies of the Head and Neck
    Eur Arch Otorhinolaryngol (2006) 263: 32–36 DOI 10.1007/s00405-005-0942-1 HEAD AND NECK ONCOLOGY L. W. J. Baijens Æ J. J. Manni Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature Received: 8 December 2004 / Accepted: 31 January 2005 / Published online: 29 June 2005 Ó Springer-Verlag 2005 Abstract Paraneoplastic syndromes rarely affect pa- patients [5, 13]. Often the paraneoplastic syndrome tients with head and neck cancer. Four patients with presents before the initial symptoms or diagnosis of the different histological types of head and neck cancer are primary malignancy or the recurrent tumour is made [5]. presented in which the primary malignancy was pre- Paraneoplastic syndromes occur in 1 to 7.4% of all ceded and/or accompanied by a paraneoplastic syn- cancer patients [7, 21]. The mechanisms of most para- drome. In the first patient erythrodermia preceded the neoplastic syndromes are not well known. Ectopic hor- diagnosis of a nasopharyngeal carcinoma. The second mone production is probably the most common patient presented with a B cell lymphoma of the mechanism [12]. Immunologic interactions in particular nasopharynx in association with the syndrome of inap- autoimmune responses play an important role in neu- propriate secretion of arginine vasopressine (Schwartz- rological paraneoplastic syndromes [1, 7, 10, 17]. In the Bartter syndrome). In the third patient paraneoplastic literature, paraneoplastic syndromes in association with polyarthritis had been diagnosed 5 months before a head and neck cancer have occasionally been reported. hypopharyngeal carcinoma was diagnosed. In the last Squamous cell carcinoma is the most common histopa- patient the paraneoplastic anti-Hu positive encephalo- thology of the primary malignancy of the head and neck myelitis was associated with a primary malignancy in the associated with paraneoplastic syndromes [12].
    [Show full text]